Pembrolizumab PK Fact Sheet

Details

Generic Name: Pembrolizumab
Trade Name: Keytruda®
Class: Antineoplastic agents, monoclonal antibody
Molecular Weight: ~149 kDa

Summary of Key Pharmacokinetic Parameters

- **Linearity/non-linearity**: Exposure increases in a dose-proportional manner within the dose range for efficacy.
- **Steady state**: Achieved after 16 weeks of repeated dosing on an every 3-week regimen.
- **Plasma half-life**: 22 days.
- **Cmax**: Not reported.
- **Cmin**: 22 µg/mL at a dose of 2 mg/kg every 3 weeks.
  
- **AUC**: 794 µg∙day/mL at a dose of 2 mg/kg every 3 weeks.
  
- **Bioavailability**: Completely bioavailable.
- **Absorption**: Administered IV.
- **Protein Binding**: Does not bind to plasma proteins in a specific manner.
- **Volume of Distribution**: ~6 L.
- **CSF:Plasma ratio**: Not determined.
- **Semen:Plasma ratio**: Not determined.
- **Renal Clearance**: Not reported.
- **Renal Impairment**: No dose adjustment required for patients with mild to moderate renal impairment.

- **Hepatic Impairment**: No dose adjustment required for patients with mild hepatic impairment.

Metabolism and Distribution

- **Metabolised by**: Catabolised through non-specific pathways.
- **Inducer of**: None reported.
- **Inhibitor of**: None reported.
- **Transported by**: None reported.
References

Unless otherwise stated (see below), information is from:

Keytruda SmPC, Merck Sharp & Dohme Ltd.

Keytruda Prescribing Information, Merck & Co., Inc.